Browse studies
Find your next paid study
3 recruiting studies matching your filters
Phase 2
A Phase II Randomized Trial of Intermittent Androgen Deprivation Therapy Alone or Combined With [177Lu]Lu-PSMA-617, With or Without Abiraterone and Prednisone, in Patients With Low-Volume Metastatic Hormone-Sensitive Prostate Cancer
This phase II trial tests leuprolide acetate alone versus in combination with 177Lu-PSMA-617, with or without abiraterone acetate and prednisone, for the treat…
Recurrent Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8Castration-Sensitive Prostate Cancer+9 more
Estimated
~$10 – $6,250
Mayo ClinicNCT07650240
Phase 2
Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide Combined With Metastasis-Directed Stereotactic Body Radiotherapy for Oligorecurrent Prostate Adenocarcinoma (ANDROMEDA)
This phase II trial compares the use of 225Ac-PSMA-617 to 177Lu-PSMA-617, along with stereotactic body radiotherapy for the treatment of prostate cancer that h…
Oligometastatic Prostate AdenocarcinomaRecurrent Prostate Adenocarcinoma
Estimated
~$10 – $6,250
Jonsson Comprehensive Cancer CenterNCT07150715
Phase 3
Randomized Phase III Trial of SBRT Versus Hypofractionated Radiotherapy for Salvage of Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma After Radical Prostatectomy
This phase III trial tests the side effects of stereotactic body radiation therapy (SBRT) compared to hypofractionated radiotherapy for treating patients with …
Biochemically Recurrent Prostate CarcinomaOligometastatic Prostate CarcinomaRecurrent Prostate Adenocarcinoma+4 more
Estimated
~$10 – $6,250
Mayo ClinicNCT06205316